Number of the records: 1
Preclinical evaluation of linear HPMA-doxorubicin conjugates with pH-sensitive drug release: Efficacy, safety and immunomodulating activity in murine model
- 1.
SYSNO ASEP 0340865 Document Type J - Journal Article R&D Document Type Journal Article Subsidiary J Článek ve WOS Title Preclinical evaluation of linear HPMA-doxorubicin conjugates with pH-sensitive drug release: Efficacy, safety and immunomodulating activity in murine model Author(s) Šírová, Milada (MBU-M) RID, ORCID
Mrkvan, Tomáš (MBU-M)
Etrych, Tomáš (UMCH-V) RID, ORCID
Chytil, Petr (UMCH-V) RID, ORCID
Rossmann, Pavel (MBU-M)
Ibrahimová, Markéta (MBU-M)
Kovář, Lubomír (MBU-M)
Ulbrich, Karel (UMCH-V) RID
Říhová, Blanka (MBU-M) RIDSource Title Pharmaceutical Research. - : Springer - ISSN 0724-8741
Roč. 27, č. 1 (2010), s. 200-208Number of pages 9 s. Language eng - English Country US - United States Keywords immunomodulation ; doxorubicin ; murine lymphoma Subject RIV EC - Immunology R&D Projects KAN200200651 GA AV ČR - Academy of Sciences of the Czech Republic (AV ČR) CEZ AV0Z50200510 - MBU-M (2005-2011) AV0Z40500505 - UMCH-V (2005-2011) UT WOS 000272905300020 DOI 10.1007/s11095-009-9999-7 Annotation Well-defined linear conjugates of HPMA copolymer and doxorubicin bound via a pH-controlled linkage can induce complete cure of already developed murine solid tumors without significant side effects, and induce development of specific anti-tumor resistance. The HPMA-doxorubicin conjugate is a good candidate for clinical trials Workplace Institute of Microbiology Contact Eliška Spurná, eliska.spurna@biomed.cas.cz, Tel.: 241 062 231 Year of Publishing 2010
Number of the records: 1